GlassScriptPhysician profile
Israel Rodriguez
NPI 1962136614
$4,241.92
in general payments reported to CMS, 2019-2025
23 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,857 · 2024: $1,964 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,839 · Education: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.24 |
| Education | $402.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $578.04 | 2023-2024 | Dupixent |
| Abbvie INC. | $504.84 | 2023-2025 | |
| Incyte Corporation | $424.40 | 2023-2024 | Opzelura |
| Amgen INC. | $372.45 | 2023-2025 | Tepezza, Otezla |
| Sun Pharmaceutical Industries INC. | $332.88 | 2023-2024 | Winlevi, Absorica Ld |
| Ucb, INC. | $324.33 | 2023-2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $295.94 | 2023-2024 | |
| Janssen Biotech, INC. | $290.78 | 2023-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $179.46 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $174.55 | 2025 | Aklief |
| Novartis Pharmaceuticals Corporation | $162.76 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $155.19 | 2023-2024 | Cabtreo, Siliq, Duobrii |
| Lilly USA, LLC | $102.58 | 2023-2024 | Taltz, Olumiant |
| Pfizer INC. | $92.87 | 2023-2024 | |
| Leo Pharma INC. | $51.83 | 2024 | Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $43.30 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $32.43 | 2023 | |
| Merz Pharmaceuticals, LLC | $25.55 | 2024 | Xeomin |
| Convatec INC. | $23.57 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $21.23 | 2025 | Xdemvy |
| Organon LLC | $20.27 | 2024 | |
| Dermavant Sciences, INC. | $19.55 | 2023 | Vtama |
| Chiesi USA, INC. | $13.12 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Israel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.